Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (17)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bowness, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bowness, P.
Related Collections
Right arrow Spondylarthropathies
Right arrow Immunogenetics
Right arrow Systemic Lupus Erythematosus and Autoimmunity
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2002; 41: 857-868
© 2002 British Society for Rheumatology


Reviews

HLA B27 in health and disease: a double-edged sword?

The 2000 Michael Mason Prize Essay

P. Bowness

Nuffield Orthopaedic Hospital, Windmill Road, Headington, Oxford OX3 7LD, UK

The strong association of the HLA class 1 allele HLA B27 with ankylosing spondylitis (AS) has been recognized for over 25 yr, however the pathogenic mechanism linking HLA B27 with AS and other spondyloarthropathies remains a mystery. We now know that the principal natural function of HLA B27 is an immunologic one, namely to bind antigenic peptides and then present them to T lymphocytes. I have shown that HLA B27 functions as an excellent antigen-presenting molecule in both spondyloarthropathy patients and healthy individuals. A working molecular model of how T cells recognize HLA B27 has been generated and tested. Evidence that T cells have a role in spondyloarthritis has also been found. First, expanded populations of T lymphocytes were found in both the blood and synovial fluid of patients with reactive arthritis (ReA). Secondly, a strong cytotoxic T-cell response to an HLA B27-restricted peptide epitope from Chlamydia trachomatis was found in a patient with ReA. This peptide, derived from a bacterium known to trigger ReA, is thus a candidate ‘arthritogenic’ peptide. We have also found evidence that HLA B27 has an unusual cell biology compared with other HLA molecules. HLA B27 demonstrates an unusual ability to form heavy chain homodimers in vitro. Dimerization is dependent upon disulphide bonding through an unpaired cysteine at position 67. Remarkably these dimers lack ß2 microglobulin, previously thought to be an essential component of all mature MHC class 1 molecules. HLA B27 homodimer formation has also been demonstrated in certain cell lines in vivo, and preliminary data suggest that significant numbers of T cells from patients with spondyloarthropathy express a ligand for HLA B27 homodimers. These findings have extended our understanding of the beneficial immunologic function of HLA B27, and have also led us to propose the testable new hypothesis that HLA B27 heavy chain dimerization may be involved in the pathogenesis of spondyloarthritis.

KEY WORDS: HLA B27, Reactive arthritis, Ankylosing spondylitis, Immunology.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Clin. Microbiol. Rev.Home page
I. Colmegna, R. Cuchacovich, and L. R. Espinoza
HLA-B27-Associated Reactive Arthritis: Pathogenetic and Clinical Considerations
Clin. Microbiol. Rev., April 1, 2004; 17(2): 348 - 369.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. N. Antoniou, S. Ford, J. D. Taurog, G. W. Butcher, and S. J. Powis
Formation of HLA-B27 Homodimers and Their Relationship to Assembly Kinetics
J. Biol. Chem., March 5, 2004; 279(10): 8895 - 8902.
[Abstract] [Full Text] [PDF]


Home page
JRSMHome page
N. J Sheehan
The ramifications of HLA-B27
J R Soc Med, January 1, 2004; 97(1): 10 - 14.
[Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.